1538 related articles for article (PubMed ID: 18522288)
1. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
2. Compliance of osteoporotic patients with different treatment regimens.
Segal E; Tamir A; Ish-Shalom S
Isr Med Assoc J; 2003 Dec; 5(12):859-62. PubMed ID: 14689753
[TBL] [Abstract][Full Text] [Related]
3. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
4. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
5. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration.
Scharla S; Oertel H; Helsberg K; Kessler F; Langer F; Nickelsen T
Curr Med Res Opin; 2006 Dec; 22(12):2393-402. PubMed ID: 17257453
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women.
Biri A; Korucuoglu U; Ilhan MN; Ciftci B; Bozkurt N; Guner H
Arch Gynecol Obstet; 2009 Apr; 279(4):505-9. PubMed ID: 18690468
[TBL] [Abstract][Full Text] [Related]
7. Self-reported compliance with osteoporosis medication-qualitative aspects and correlates.
Vytrisalova M; Blazkova S; Palicka V; Vlcek J; Cejkova M; Hala T; Pavelka K; Koblihova H
Maturitas; 2008; 60(3-4):223-9. PubMed ID: 18774663
[TBL] [Abstract][Full Text] [Related]
8. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
Turbí C; Herrero-Beaumont G; Acebes JC; Torrijos A; Graña J; Miguélez R; Sacristán J; Marín F
Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
[TBL] [Abstract][Full Text] [Related]
9. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
10. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
[TBL] [Abstract][Full Text] [Related]
11. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO).
Jakob F; Marín F; Martín-Mola E; Torgerson D; Fardellone P; Adami S; Thalassinos NC; Sykes D; Melo-Gomes J; Chinn C; Nicholson T; Cooper C
QJM; 2006 Aug; 99(8):531-43. PubMed ID: 16861718
[TBL] [Abstract][Full Text] [Related]
12. Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.
Neven P; Quail D; Marin F; Creatsas G; Depypere H; Rechberger T; Liu-Léage S; Pavo I; Schmitt H; Nickelsen T
Maturitas; 2005 Oct; 52(2):87-101. PubMed ID: 15967604
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study.
Yoh K; Hamaya E; Urushihara H; Iikuni N; Yamamoto T; Taketsuna M; Miyauchi A; Sowa H; Tanaka K
Curr Med Res Opin; 2012 Nov; 28(11):1757-66. PubMed ID: 23035693
[TBL] [Abstract][Full Text] [Related]
14. Effect of raloxifene on the vaginal epithelium of postmenopausal women.
Delmanto A; Nahas-Neto J; Nahas EA; de Oliveira ML; Fernandes CE; Traiman P
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):187-92. PubMed ID: 18400357
[TBL] [Abstract][Full Text] [Related]
15. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
16. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in osteoporotic women with inadequate clinical response to antiresorptive drugs: results from the ICARO study.
Barbagallo M; Dominguez LJ; Maugeri D; Isaia G; Silvestri S; Bevilacqua M; Adami S;
Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):24-7. PubMed ID: 18180604
[TBL] [Abstract][Full Text] [Related]
18. Knowledge and compliance from patients with postmenopausal osteoporosis treatment.
Palacios S; Sánchez-Borrego R; Neyro JL; Quereda F; Vázquez F; Pérez M; Pérez M
Menopause Int; 2009 Sep; 15(3):113-9. PubMed ID: 19723681
[TBL] [Abstract][Full Text] [Related]
19. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
[TBL] [Abstract][Full Text] [Related]
20. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.
Gol M; Baris N; Guneri S; Posaci C
Am J Obstet Gynecol; 2006 May; 194(5):1249-54. PubMed ID: 16647907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
